

Bridging preclinical to clinical development

Leveraging proven strategies for holistic biomarkers, advanced modalities and technology insights

11:30 – 13:00 - Registration and networking lunch

13:00 – 14:00 Welcome and opening session

Raphaël Conz, Managing Director, Office for Economic Affairs and Innovation (SPEI), State of Vaud

– Welcome address

Michael Altorfer, CEO, Swiss Biotech Association

– As simple as possible, but not simpler

Julia Djonova, Head of the Advanced Therapy Medicinal Products (ATMP) Department, Swissmedic

– Accelerating ATMP development in Switzerland – Clarity and confidence through regulatory refinement

Stefano Romanelli, Senior Government Affairs Manager, EUCOPE

– How the EU legislative environment will shape the future of biotech, from R&D to access

Moderators

- Marta Gehring, Special Projects and Lead, Swiss Biotech Insight Events, Swiss Biotech Association
- Antoine Mialhe, Senior Managing Director, FTI Consulting

14:00 – 15:15 - Discovery to preclinical innovation: Setting the scientific foundation

Dan Snell, SVP Research and Preclinical Development, Numab Therapeutics

– Navigating the discovery and development of novel multispecific antibodies: How form follows function

Giusy Di Conza, Head of Research, iOnctura

– Innovating small molecule therapies for neglected and hard-to-treat cancers

Stephanie Jungmichel, Head of Pharmacology, CDR-Life

– Advancing tumor-specific T Cell engagers: Overcoming challenging antigens and innovative human cell-based assays for IND

James Munday, PhD, Head of Global Immunology and Immunotoxicology, Labcorp

– Applying context if use considerations in assay development from discovery to pre-clinical assay development

Moderators

- Fernanda Herrera, MD, Professor and Head of Service, Radio-oncology, Vaud University Hospital (CHUV)
- Stephane Sidobre, PhD, VP Bioanalytical and CMC Services, Labcorp

15:45 – 17:15 Strategy & clinical execution: Linking science to business impact

Frédéric Levy, Chief Scientific Officer, Debiopharm

– From early science to global therapies: Debiopharm's innovation strategy in ADCs

Anissa Fries, Lead Scientist Flow Cytometry, Labcorp

– Evaluation of rituximab interference with Labcorp CLL ERIC MRD assay

Anthony Guihur, Staff Scientist, Genomics, Labcorp

– Effective personalized medicine and disease monitoring with circulating DNA biomarkers

Shabir Hasham, Chief Medical Officer, Santhera

– Advancing the pipeline: Long-term safety, GUARDIAN trial, and future rare disease opportunities

Moderators

- Rebecca Weil, PhD, Chief Commercial Officer, Oculis
- Nicolas Anfossi, PhD, Global Director, Flow Cytometry, Labcorp

17:15 – 18:30 - Networking cocktail